Is MRNA stock a sell today? The S&P 500 has hit record levels this year and many stocks have generated fantastic returns for investors. Among the S&P 500's worst performers thus far in 2024 are ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate. The STIMULUS-MDS2 trial was ...